Press Releases

C-reactive Protein Testing Market to Reach US$ 10.6 Bn by 2030

Share This Article

The global C-reactive Protein Testing market is expected to grow at a CAGR of around 0.6% over the forecast period 2021 to 2030 and expected to reach the market value of around US$ 10.6 billion by 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38686

Growth Factors

 The market growth can be attributed to substantial research activities to explore the applications of C-reactive protein (CRP) testing coupled with the presence of private as well as public agencies which grant funds to expedite the research proceedings in this arena.

A rise in the number of strategic deals and developments coupled with the increase in investments for R&D of C-reactive protein testing is expected to drive the market significantly. The ongoing COVID-19 pandemic has affected the CRP testing market to a great extent. As CRP is considered to be the determining biomarker for the severity of infection/inflammation, the market is witnessing increased demand for CRP testing services and products. Major operating companies such as Abbott offer supportive tools for CRP testing for SARS-CoV-2 infection.

Report Coverage

Report Scope Details
Market Size USD 10.6 billion by 2030
Growth Rate CAGR of 0.6% From 2021 to 2030
Base Year 2021
Forecast Period 2021 to 2030
Segments Covered Assay type, Detection range, Disease type, End-use
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned Thermo Fisher Scientific, Inc.; F. Hoffmann-La Roche Ltd; Danaher; Quest Diagnostics; Siemens Healthineers AG; Abbott; Merck KGaAA; Zoetis; Ortho Clinical Diagnostics; Getein Biotech, Inc; HORIBA, Ltd; Randox Laboratories Ltd; BODITECH MED, INC.; Aidian

By Assay Type Analysis

The immunoturbidimetric assays dominated the market and accounted for the largest revenue share of 48.5% in 2020. The segment is anticipated to further grow during the forecast period.

Technological advancements in immunoturbidimetric assays are expected to fuel market growth in the coming years. Researchers across the world are actively involved in the development of advanced and innovative assays to support rapid and accurate CRP testing.

By Detection Range Analysis

The hs-CRP segment dominated the CRP testing market and accounted for the largest revenue share of 42.8% in 2020. The segment is anticipated to witness a CAGR of 0.3% from 2021 – 2028.

American Heart Association (AHA) and Centers for Disease Control and Prevention (CDC), hs-CRP acts as an independent marker that facilitates in the estimation of cardiovascular disorders such as myocardial infarction.

By Disease Type Analysis

The Cardiovascular diseases (CVD) segment lead the market and accounted for the largest revenue share of 22.8% in 2020. An increase in the prevalence of CVDs is the major factor contributing to the growth of the market. Adoption of a sedentary lifestyle, obesity, hypertension, and diabetes are few risk factors associated with CVDs.

The cancer segment held the second-largest revenue share in 2020. It is a crucial public health burden across the globe. According to the WHO, there are more than 1.9 million deaths and 3.7 million new cancer cases every year in the European region, hence, there is a need for large-scale adoption of POC CRP testing solutions to aid in the management of cancer in developed and developing countries across the globe.

By End-use Analysis

 The hospitals segment dominated the market and lead for the largest revenue share of 31.2% in 2020. The growth of the hospitals segment can be attributed to the rising penetration of CRP testing in hospitals, especially in developing regions across the world.

The clinics segment held a substantial market share throughout the analysis period. CRP testing technology has expanded in the past few years with noteworthy developments in areas of point-of-care and hs-CRP.

By Regional Analysis

North America dominated the C-reactive protein testing market and accounted for the highest revenue share of 40.5% in 2020. Increasing adoption of innovative, advanced technology and high focus on clinical research in North America are among the factors driving the market.

According to the American Cancer Society, prostate cancer is the second most diagnosed cancer in the U.S. and the third leading cause of death in men. Estimates from the same source also indicated that one in 41 men in the U.S. will die as a result of prostate cancer.

Key Players

  • Thermo Fisher Scientific, inc.
  • F. Hoffmann-La Roche Ltd.
  • Danaher
  • Quest Diagnostics
  • Siemens Healthineers AG
  • Abbott
  • Merck KGaAA
  • Zoetis
  • Ortho Clinical Diagnostics
  • Getein Biotech, Inc.
  • HORIBA, Ltd
  • Randox Laboratories Ltd.
  • BODITECH MED, INC.
  • Aidian

Market Segmentation

  • Assay Type
    • Immunoturbidimetric Assay
    • ELISA
      • Clinical
      • Non-clinical
    • Chemiluminescence Immunoassay
    • Others
  • Detection Range
    • hs-CRP
    • Conventional CRP
    • cCRP
  • Disease Area
    • Cardiovascular Diseases
    • Cancer
    • Rheumatoid Arthritis
    • Inflammatory Bowel Disease
    • Endometriosis
    • Lupus
    • Others
  • End-use
    • Clinics
      • By Entity
        • Physician Offices
        • Small Clinics
        • Others
      • By Settings
        • Urban Setting
        • Rural Setting
    • Hospitals
      • Urban Setting
      • Rural Setting
    • Laboratories
      • Urban Setting
      • Rural Setting
    • Assisted Living Healthcare Facilities
      • Urban Setting
      • Rural Setting
    • Home
    • Others
  • Regional
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
    • Asia Pacific
      • China
      • Japan
    • Latin America
      • Brazil
    • Middle East and Africa (MEA)
      • South Africa

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38686

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global C-reactive Protein Testing Market, By Assay Type

7.1.  C-reactive Protein Testing Market, by Assay Type, 2021-2030

7.1.1.    Immunoturbidimetric Assay

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    ELISA

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Chemiluminescence Immunoassay

7.1.3.1.        Market Revenue and Forecast (2017-2030)

7.1.4.    Others

7.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global C-reactive Protein Testing Market, By Detection Range

8.1.  C-reactive Protein Testing Market, by Detection Range, 2021-2030

8.1.1.    hs-CRP

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Conventional CRP

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    cCRP

8.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global C-reactive Protein Testing Market, By Disease Area

9.1.  C-reactive Protein Testing Market, by Disease Area, 2021-2030

9.1.1.    Cardiovascular Diseases

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Cancer

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Rheumatoid Arthritis

9.1.3.1.        Market Revenue and Forecast (2017-2030)

9.1.4.    Inflammatory Bowel Disease

9.1.4.1.        Market Revenue and Forecast (2017-2030)

9.1.5.    Endometriosis

9.1.5.1.        Market Revenue and Forecast (2017-2030)

9.1.6.    Lupus

9.1.6.1.        Market Revenue and Forecast (2017-2030)

9.1.7.    Others

9.1.7.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global C-reactive Protein Testing Market, By Capacitor

10.1.        C-reactive Protein Testing Market, by Capacitor, 2021-2030

10.1.1.  Clinics

10.1.1.1.      Market Revenue and Forecast (2017-2030)

10.1.2.  Hospitals

10.1.2.1.      Market Revenue and Forecast (2017-2030)

10.1.3.  Laboratories

10.1.3.1.      Market Revenue and Forecast (2017-2030)

10.1.4.  Assisted Living Healthcare Facilities

10.1.4.1.      Market Revenue and Forecast (2017-2030)

10.1.5.  Home

10.1.5.1.      Market Revenue and Forecast (2017-2030)

10.1.6.  Others

10.1.6.1.      Market Revenue and Forecast (2017-2030)

Chapter 11.      Global C-reactive Protein Testing Market, Regional Estimates and Trend Forecast

11.1.        North America

11.1.1.  Market Revenue and Forecast, by Assay Type (2017-2030)

11.1.2.  Market Revenue and Forecast, by Detection Range (2017-2030)

11.1.3.  Market Revenue and Forecast, by Disease Area (2017-2030)

11.1.4.  Market Revenue and Forecast, by Capacitor (2017-2030)

11.1.5.  U.S.

11.1.5.1.      Market Revenue and Forecast, by Assay Type (2017-2030)

11.1.5.2.      Market Revenue and Forecast, by Detection Range (2017-2030)

11.1.5.3.      Market Revenue and Forecast, by Disease Area (2017-2030)

11.1.5.4.      Market Revenue and Forecast, by Capacitor (2017-2030)

11.1.6.  Rest of North America

11.1.6.1.      Market Revenue and Forecast, by Assay Type (2017-2030)

11.1.6.2.      Market Revenue and Forecast, by Detection Range (2017-2030)

11.1.6.3.      Market Revenue and Forecast, by Disease Area (2017-2030)

11.1.6.4.      Market Revenue and Forecast, by Capacitor (2017-2030)

11.2.        Europe

11.2.1.  Market Revenue and Forecast, by Assay Type (2017-2030)

11.2.2.  Market Revenue and Forecast, by Detection Range (2017-2030)

11.2.3.  Market Revenue and Forecast, by Disease Area (2017-2030)

11.2.4.  Market Revenue and Forecast, by Capacitor (2017-2030)

11.2.5.  UK

11.2.5.1.      Market Revenue and Forecast, by Assay Type (2017-2030)

11.2.5.2.      Market Revenue and Forecast, by Detection Range (2017-2030)

11.2.5.3.      Market Revenue and Forecast, by Disease Area (2017-2030)

11.2.5.4.      Market Revenue and Forecast, by Capacitor (2017-2030)

11.2.6.  Germany

11.2.6.1.      Market Revenue and Forecast, by Assay Type (2017-2030)

11.2.6.2.      Market Revenue and Forecast, by Detection Range (2017-2030)

11.2.6.3.      Market Revenue and Forecast, by Disease Area (2017-2030)

11.2.6.4.      Market Revenue and Forecast, by Capacitor (2017-2030)

11.2.7.  France

11.2.7.1.      Market Revenue and Forecast, by Assay Type (2017-2030)

11.2.7.2.      Market Revenue and Forecast, by Detection Range (2017-2030)

11.2.7.3.      Market Revenue and Forecast, by Disease Area (2017-2030)

11.2.7.4.      Market Revenue and Forecast, by Capacitor (2017-2030)

11.2.8.  Rest of Europe

11.2.8.1.      Market Revenue and Forecast, by Assay Type (2017-2030)

11.2.8.2.      Market Revenue and Forecast, by Detection Range (2017-2030)

11.2.8.3.      Market Revenue and Forecast, by Disease Area (2017-2030)

11.2.8.4.      Market Revenue and Forecast, by Capacitor (2017-2030)

11.3.        APAC

11.3.1.  Market Revenue and Forecast, by Assay Type (2017-2030)

11.3.2.  Market Revenue and Forecast, by Detection Range (2017-2030)

11.3.3.  Market Revenue and Forecast, by Disease Area (2017-2030)

11.3.4.  Market Revenue and Forecast, by Capacitor (2017-2030)

11.3.5.  India

11.3.5.1.      Market Revenue and Forecast, by Assay Type (2017-2030)

11.3.5.2.      Market Revenue and Forecast, by Detection Range (2017-2030)

11.3.5.3.      Market Revenue and Forecast, by Disease Area (2017-2030)

11.3.5.4.      Market Revenue and Forecast, by Capacitor (2017-2030)

11.3.6.  China

11.3.6.1.      Market Revenue and Forecast, by Assay Type (2017-2030)

11.3.6.2.      Market Revenue and Forecast, by Detection Range (2017-2030)

11.3.6.3.      Market Revenue and Forecast, by Disease Area (2017-2030)

11.3.6.4.      Market Revenue and Forecast, by Capacitor (2017-2030)

11.3.7.  Japan

11.3.7.1.      Market Revenue and Forecast, by Assay Type (2017-2030)

11.3.7.2.      Market Revenue and Forecast, by Detection Range (2017-2030)

11.3.7.3.      Market Revenue and Forecast, by Disease Area (2017-2030)

11.3.7.4.      Market Revenue and Forecast, by Capacitor (2017-2030)

11.3.8.  Rest of APAC

11.3.8.1.      Market Revenue and Forecast, by Assay Type (2017-2030)

11.3.8.2.      Market Revenue and Forecast, by Detection Range (2017-2030)

11.3.8.3.      Market Revenue and Forecast, by Disease Area (2017-2030)

11.3.8.4.      Market Revenue and Forecast, by Capacitor (2017-2030)

11.4.        MEA

11.4.1.  Market Revenue and Forecast, by Assay Type (2017-2030)

11.4.2.  Market Revenue and Forecast, by Detection Range (2017-2030)

11.4.3.  Market Revenue and Forecast, by Disease Area (2017-2030)

11.4.4.  Market Revenue and Forecast, by Capacitor (2017-2030)

11.4.5.  GCC

11.4.5.1.      Market Revenue and Forecast, by Assay Type (2017-2030)

11.4.5.2.      Market Revenue and Forecast, by Detection Range (2017-2030)

11.4.5.3.      Market Revenue and Forecast, by Disease Area (2017-2030)

11.4.5.4.      Market Revenue and Forecast, by Capacitor (2017-2030)

11.4.6.  North Africa

11.4.6.1.      Market Revenue and Forecast, by Assay Type (2017-2030)

11.4.6.2.      Market Revenue and Forecast, by Detection Range (2017-2030)

11.4.6.3.      Market Revenue and Forecast, by Disease Area (2017-2030)

11.4.6.4.      Market Revenue and Forecast, by Capacitor (2017-2030)

11.4.7.  South Africa

11.4.7.1.      Market Revenue and Forecast, by Assay Type (2017-2030)

11.4.7.2.      Market Revenue and Forecast, by Detection Range (2017-2030)

11.4.7.3.      Market Revenue and Forecast, by Disease Area (2017-2030)

11.4.7.4.      Market Revenue and Forecast, by Capacitor (2017-2030)

11.4.8.  Rest of MEA

11.4.8.1.      Market Revenue and Forecast, by Assay Type (2017-2030)

11.4.8.2.      Market Revenue and Forecast, by Detection Range (2017-2030)

11.4.8.3.      Market Revenue and Forecast, by Disease Area (2017-2030)

11.4.8.4.      Market Revenue and Forecast, by Capacitor (2017-2030)

11.5.        Latin America

11.5.1.  Market Revenue and Forecast, by Assay Type (2017-2030)

11.5.2.  Market Revenue and Forecast, by Detection Range (2017-2030)

11.5.3.  Market Revenue and Forecast, by Disease Area (2017-2030)

11.5.4.  Market Revenue and Forecast, by Capacitor (2017-2030)

11.5.5.  Brazil

11.5.5.1.      Market Revenue and Forecast, by Assay Type (2017-2030)

11.5.5.2.      Market Revenue and Forecast, by Detection Range (2017-2030)

11.5.5.3.      Market Revenue and Forecast, by Disease Area (2017-2030)

11.5.5.4.      Market Revenue and Forecast, by Capacitor (2017-2030)

11.5.6.  Rest of LATAM

11.5.6.1.      Market Revenue and Forecast, by Assay Type (2017-2030)

11.5.6.2.      Market Revenue and Forecast, by Detection Range (2017-2030)

11.5.6.3.      Market Revenue and Forecast, by Disease Area (2017-2030)

11.5.6.4.      Market Revenue and Forecast, by Capacitor (2017-2030)

Chapter 12.  Company Profiles

12.1.              Thermo Fisher Scientific, inc.

12.1.1.  Company Overview

12.1.2.  Product Offerings

12.1.3.  Financial Performance

12.1.4.  Recent Initiatives

12.2.              F. Hoffmann-La Roche Ltd.

12.2.1.  Company Overview

12.2.2.  Product Offerings

12.2.3.  Financial Performance

12.2.4.  Recent Initiatives

12.3.              Danaher

12.3.1.  Company Overview

12.3.2.  Product Offerings

12.3.3.  Financial Performance

12.3.4.  Recent Initiatives

12.4.              Quest Diagnostics

12.4.1.  Company Overview

12.4.2.  Product Offerings

12.4.3.  Financial Performance

12.4.4.  Recent Initiatives

12.5.              Siemens Healthineers AG

12.5.1.  Company Overview

12.5.2.  Product Offerings

12.5.3.  Financial Performance

12.5.4.  Recent Initiatives

12.6.              Abbott

12.6.1.  Company Overview

12.6.2.  Product Offerings

12.6.3.  Financial Performance

12.6.4.  Recent Initiatives

12.7.              Merck KGaAA

12.7.1.  Company Overview

12.7.2.  Product Offerings

12.7.3.  Financial Performance

12.7.4.  Recent Initiatives

12.8.              Zoetis

12.8.1.  Company Overview

12.8.2.  Product Offerings

12.8.3.  Financial Performance

12.8.4.  Recent Initiatives

12.9.              Ortho Clinical Diagnostics

12.9.1.  Company Overview

12.9.2.  Product Offerings

12.9.3.  Financial Performance

12.9.4.  Recent Initiatives

12.10.           Getein Biotech, Inc.

12.10.1.               Company Overview

12.10.2.               Product Offerings

12.10.3.               Financial Performance

12.10.4.               Recent Initiatives

12.11.           HORIBA, Ltd

12.11.1.               Company Overview

12.11.2.               Product Offerings

12.11.3.               Financial Performance

12.11.4.               Recent Initiatives

Chapter 13.  Research Methodology

13.1.              Primary Research

13.2.              Secondary Research

13.3.              Assumptions

Chapter 14.  Appendix

14.1.              About Us

14.2.              Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38686

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com

Show More

Related Articles

Back to top button